Valuation Trading Multiples & Precedent Transactions: Genomic Sequencing and Diagnostics Companies
Valuation benchmarks for Genomic Sequencing and Diagnostics Companies. Access public trading comps, EV/EBITDA acquisition multiples, and private market data for pitch books and valuation analysis.
1.1 - Genomic Sequencing and Diagnostics Companies Market Context & Valuation Drivers
Companies in this trading comparable group provide clinical genomic sequencing and precision oncology diagnostics, monetizing test volumes, sequencing services, and related informatics. Offerings span liquid biopsy assays, comprehensive genomic profiling, and tumor-normal analyses that guide treatment decisions and research. They are grouped together because they operate at the intersection of genomics and personalized medicine, with similar regulatory exposure, reimbursement dynamics, and laboratory services revenue models that support valuation benchmarking.
Typical capabilities include FDA-approved companion diagnostics, blood-based liquid biopsy tests for colorectal screening and tumor profiling, whole exome and transcriptome sequencing, and tumor-informed minimal residual disease assays. Providers augment testing with cryogenic biobanking and sample storage, high-throughput laboratory automation and sample management, and cloud informatics for workflow orchestration, data analysis, and reporting. Many also offer custom genomic services and bioanalytical support for clinical trials and translational research.
Primary customers include oncology providers and health systems adopting precision diagnostics, biopharmaceutical companies running clinical trials and companion diagnostic programs, and academic medical centers. Key valuation drivers are test volume growth, payer reimbursement coverage and ASPs, gross margin expansion from scale and automation, and recurring services and informatics revenue mix. Customer retention in biopharma contracts and turnaround times also influence commercial traction and pricing power.
2. Valuation Analysis: Public Trading Comps & Multiples for Genomic Sequencing and Diagnostics Companies companies
2.1 - Public Peer Groups & Median Valuation Multiples for Genomic Sequencing and Diagnostics Companies sector
Comparable group 1: Genomic Sequencing and Diagnostics Companies
Guardant Health
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of blood and tissue tests, data sets, and analytics with a focus on the treatment and management of cancer through precision oncology and advanced research platforms.
- Key Products:
- Guardant360 CDx Test: FDA-approved liquid biopsy test for identifying patients with specific gene mutations to guide treatment decisions
- GuardantOMNI: Liquid biopsy test for comprehensive genomic profiling of tumors in cancer patients
- Shield Test: Blood-based test for colorectal cancer screening
- Guardant Reveal: Blood-only liquid biopsy test for detecting residual and recurrent colorectal cancer
- GuardantINFINITY: High-definition liquid biopsy test for advanced-stage solid tumors.
Azenta
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of life sciences services including genomics, cryogenic storage, automation, and informatics, enabling organizations to accelerate scientific discovery and bring impactful breakthroughs and therapies to market efficiently.
- Key Products:
- Cryogenic Storage Solutions: Advanced cold-chain storage services for biological samples
- Genomic Services: Comprehensive genomic analysis and sequencing services
- Automation Solutions: High-efficiency automation tools for sample management and laboratory workflows
- Informatics Solutions: Cloud-based software for lab workflow and bio-sample data management
- Sample Lifecycle Management: Integrated solutions for sample preparation, storage, and management.